Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant greater » significantly greater (Expand Search), significant gender (Expand Search), significant broader (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant greater » significantly greater (Expand Search), significant gender (Expand Search), significant broader (Expand Search)
greater decrease » greatest decrease (Expand Search), greater increase (Expand Search), greater disease (Expand Search)
-
2301
-
2302
Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.
Published 2025Subjects: -
2303
-
2304
The characteristics of patient groups were used to prove the method’s applicability.
Published 2025Subjects: -
2305
-
2306
-
2307
-
2308
ROS, K<sup>+</sup> efflux and cathepsin B are required for NLRP3 activation.
Published 2025Subjects: -
2309
-
2310
-
2311
-
2312
Differences in health-related quality of life indexes after disease onset between groups.
Published 2025Subjects: -
2313
Changes in subcutaneous fat thickness and muscle mass (Approximately here).
Published 2025Subjects: -
2314
-
2315
-
2316
Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.
Published 2025Subjects: -
2317
-
2318
-
2319
-
2320